List of works - Nils von Hentig

A comparison of the steady-state pharmacokinetics of nevirapine in men, nonpregnant women and women in late pregnancy ⬇️

scientific article published in November 2006

A review of current literature on second-generation, sucrose-formulated, full-length recombinant factor VIII.

scientific article published on July 2009

Association of saquinavir plasma concentrations with side effects but not with antiretroviral outcome in patients infected with protease inhibitor-susceptible human immunodeficiency virus type 1

scientific article

Atazanavir plasma concentrations are impaired in HIV-1-infected adults simultaneously taking a methadone oral solution in a once-daily observed therapy setting

scientific article published on 24 December 2009

Atazanavir/ritonavir: a review of its use in HIV therapy

scientific article published on February 2008

Clinical use of cobicistat as a pharmacoenhancer of human immunodeficiency virus therapy

scientific article

Cross-sectional analysis of the influence of currently known pharmacogenetic modulators on opioid therapy in outpatient pain centers

scientific article

Cross-sectional assessment of the consequences of a GTP cyclohydrolase 1 haplotype for specialized tertiary outpatient pain care

scientific article published in November 2009

Cytochrome P450 3A inhibition by atazanavir and ritonavir, but not demography or drug formulation, influences saquinavir population pharmacokinetics in human immunodeficiency virus type 1-infected adults

scientific article published on 15 June 2009

Daily dosing of tacrolimus in patients treated with HIV-1 therapy containing a ritonavir-boosted protease inhibitor or raltegravir

scientific article published on 4 March 2010

Decrease of atazanavir and lopinavir plasma concentrations in a boosted double human immunodeficiency virus protease inhibitor salvage regimen

scientific article published on 14 April 2008

Genetic variants altering dopamine D2 receptor expression or function modulate the risk of opiate addiction and the dosage requirements of methadone substitution

scientific article published in June 2009

Higher pain scores, similar opioid doses and side effects associated with antipyretic analgesics in specialised tertiary pain care

scientific article published on 20 May 2010

Immune Response after Two Doses of the Novel Split Virion, Adjuvanted Pandemic H1N1 Influenza A Vaccine in HIV-1-Infected Patients ⬇️

scientific article published on January 1, 2011

Impact of HIV-1 replication on immunological evolution during long-term dual-boosted protease inhibitor therapy

scientific article

Lopinavir/ritonavir pharmacokinetics, efficacy, and safety in HIV and hepatitis B or C coinfected adults without symptoms of hepatic impairment

scientific article published on April 2014

Lopinavir/ritonavir: appraisal of its use in HIV therapy

scientific article published on April 2007

Pharmacokinetics and tolerability of a combination of indinavir, lopinavir and ritonavir in multiply pretreated HIV-1 infected adults.

scientific article published in June 2006

Pharmacokinetics of saquinavir, atazanavir, and ritonavir in a twice-daily boosted double-protease inhibitor regimen

scientific article published on 12 February 2007

Pharmacokinetics, safety and efficacy of saquinavir/ ritonavir 1,000/100 mg twice daily as HIV type-1 therapy and transmission prophylaxis in pregnancy

scientific article published in January 2008

Platelet-leucocyte adhesion markers before and after the initiation of antiretroviral therapy with HIV protease inhibitors

scientific article published on 27 August 2008

Safety of pharmacoenhancers for HIV therapy ⬇️

scientific article published on September 1, 2012

Saquinavir drug exposure is not impaired by the boosted double protease inhibitor combination of lopinavir/ritonavir

scientific article published in February 2004

Sequential population pharmacokinetic modeling of lopinavir and ritonavir in healthy volunteers and assessment of different dosing strategies

scientific article

Significant effects of tipranavir on platelet aggregation and thromboxane B2 formation in vitro and in vivo

scientific article published on 21 December 2007

The steady-state pharmacokinetics of atazanavir/ritonavir in HIV-1-infected adult outpatients is not affected by gender-related co-factors

scientific article published on 13 May 2008

List of works by Nils von Hentig

A comparison of the steady-state pharmacokinetics of nevirapine in men, nonpregnant women and women in late pregnancy ⬇️

A review of current literature on second-generation, sucrose-formulated, full-length recombinant factor VIII.

Association of saquinavir plasma concentrations with side effects but not with antiretroviral outcome in patients infected with protease inhibitor-susceptible human immunodeficiency virus type 1

Atazanavir plasma concentrations are impaired in HIV-1-infected adults simultaneously taking a methadone oral solution in a once-daily observed therapy setting

Atazanavir/ritonavir: a review of its use in HIV therapy

Clinical use of cobicistat as a pharmacoenhancer of human immunodeficiency virus therapy

Cross-sectional analysis of the influence of currently known pharmacogenetic modulators on opioid therapy in outpatient pain centers

Cross-sectional assessment of the consequences of a GTP cyclohydrolase 1 haplotype for specialized tertiary outpatient pain care

Cytochrome P450 3A inhibition by atazanavir and ritonavir, but not demography or drug formulation, influences saquinavir population pharmacokinetics in human immunodeficiency virus type 1-infected adults

Daily dosing of tacrolimus in patients treated with HIV-1 therapy containing a ritonavir-boosted protease inhibitor or raltegravir

Decrease of atazanavir and lopinavir plasma concentrations in a boosted double human immunodeficiency virus protease inhibitor salvage regimen

Genetic variants altering dopamine D2 receptor expression or function modulate the risk of opiate addiction and the dosage requirements of methadone substitution

Higher pain scores, similar opioid doses and side effects associated with antipyretic analgesics in specialised tertiary pain care

Immune Response after Two Doses of the Novel Split Virion, Adjuvanted Pandemic H1N1 Influenza A Vaccine in HIV-1-Infected Patients ⬇️

Impact of HIV-1 replication on immunological evolution during long-term dual-boosted protease inhibitor therapy

Lopinavir/ritonavir pharmacokinetics, efficacy, and safety in HIV and hepatitis B or C coinfected adults without symptoms of hepatic impairment

Lopinavir/ritonavir: appraisal of its use in HIV therapy

Pharmacokinetics and tolerability of a combination of indinavir, lopinavir and ritonavir in multiply pretreated HIV-1 infected adults.

Pharmacokinetics of saquinavir, atazanavir, and ritonavir in a twice-daily boosted double-protease inhibitor regimen

Pharmacokinetics, safety and efficacy of saquinavir/ ritonavir 1,000/100 mg twice daily as HIV type-1 therapy and transmission prophylaxis in pregnancy

Platelet-leucocyte adhesion markers before and after the initiation of antiretroviral therapy with HIV protease inhibitors

Safety of pharmacoenhancers for HIV therapy ⬇️

Saquinavir drug exposure is not impaired by the boosted double protease inhibitor combination of lopinavir/ritonavir

Sequential population pharmacokinetic modeling of lopinavir and ritonavir in healthy volunteers and assessment of different dosing strategies

Significant effects of tipranavir on platelet aggregation and thromboxane B2 formation in vitro and in vivo

The steady-state pharmacokinetics of atazanavir/ritonavir in HIV-1-infected adult outpatients is not affected by gender-related co-factors